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Mutations in IL36RN/IL1F5 Are Associated with the
Severe Episodic Inflammatory Skin Disease
Known as Generalized Pustular Psoriasis
Alexandros Onoufriadis,1,4 Michael A. Simpson,1,4 Andrew E. Pink,2 Paola Di Meglio,2
Catherine H. Smith,2 Venu Pullabhatla,1 Jo Knight,1 Sarah L. Spain,1 Frank O. Nestle,2
A. David Burden,3 Francesca Capon,1 Richard C. Trembath,1,* and Jonathan N. Barker2,*
Generalized pustular psoriasis (GPP) is a rare and yet potentially lethal clinical variant of psoriasis, characterized by the formation of
sterile cutaneous pustules, neutrophilia, fever and features of systemic inflammation. We sequenced the exomes of five unrelated indi-
viduals diagnosed with GPP. Nonsynonymous, splice-site, insertion, and deletion variants with an estimated population frequency of
<0.01 were considered as candidate pathogenic mutations. A homozygous c.338C>T (p.Ser113Leu) missense substitution of IL36RN
was identified in two individuals, with a third subject found to be a compound heterozygote for c.338C>T (p.Ser113Leu) and
a c.142C>T (p.Arg48Trp) missense substitution. IL36RN (previously known as IL1F5) encodes an IL-1 family receptor antagonist, which
opposes the activity of the IL-36A and IL-36G innate cytokines. Homology searches revealed that GPP mutations alter evolutionarily
conserved residues. Homozygosity for the c.338C>T (p.Ser113Leu) variant is associated with an elevated proinflammatory response
following ex vivo stimulation with IL36A. These findings suggest loss of function of IL36RN as the genetic basis of GPP and implicate
innate immune dysregulation in this severe episodic inflammatory disease, thereby highlighting IL-1 signaling as a potential target for
therapeutic intervention.Generalized pustular psoriasis (GPP) is a rare and poten-
tially life-threatening disease characterized by episodic,
widespread skin inflammation with pustule development
associated with marked systemic features (Figure 1). Acute
attacks are associated with pregnancy andmay be triggered
by infection and exposure to drugs. GPP may be the only
manifestation of disease or occur with other forms of psori-
asis, including psoriasis vulgaris (PV) and palmar-plantar
pustulosis (PPP).1 Although GPP is classified as a variant
of psoriasis, the striking clinical and histological differ-
ences indicate that it is likely to be a disease of distinct
etiology.
Here, we sought to identify disease-causal alleles for GPP
by using an established exome-sequencing strategy.2 We
selected five unrelated affected individuals with GPP
(Table 1) on the basis of the following criteria: (1) recur-
rent, severe GPP requiring hospital admission; (2) absence
of associated PV; and (3) absence of the HLA-Cw*0602
allele, the major genetic determinant of PV, at the HLA-C
locus.3 The clinical features of each of the five subjects
are presented in Table 1. None had a family history of
GPP. All subjects provided full written consent, and ethical
approval for this study was obtained from St Thomas’
Hospital Research Ethics Committee (reference 06/
Q0702/7).
DNA was extracted from blood, and whole-exome
capture was performed by in-solution hybridization fol-
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432 The American Journal of Human Genetics 89, 432–437, Septembof genomic DNA was sheared via focused acoustic tech-
nology (Covaris), yielding a mean fragment size of
150 bp. Fragment ends were repaired and sequencing adap-
tors were ligated. The sequence library was hybridized for
24 hr with biotinylated 120 bp RNA probes designed
against coding regions of the genome (Agilent). Streptavi-
din-coated magnetic beads were utilized to retain DNA
bound to the RNA probes, while unbound DNA was
washed off. The exome-enriched pool of DNA was then
eluted and amplified with a low-cycle PCR. Finally, the en-
riched DNA fragments were sequenced with 76 bp paired-
end reads on the Illumina GAIIx platform. The resulting
reads were aligned to the reference human genome
(hg18, NCBI build 36) with Novoalign (Novocraft Technol-
ogies). Over 4.7 Gb of sequence was generated for each
subject, such that > 75% of the coding bases of the
GENCODE-defined exome were represented by at least
20 reads (Table S1 available online). Single-nucleotide sub-
stitutions and small insertion/deletion variants were iden-
tified with Samtools4 and annotated with respect to coding
genes with the Annovar software package5 (Table S2).
Because vertical transmission has not been reported for
GPP, and the proband GPP-01 II-5 is the offspring of con-
sanguineous parents (Figure 2), we prioritized analysis of
the exomevariant profileswith amodel of a rare autosomal-
recessive inheritance. This analysis required the presence
of at least one homozygous or two heterozygous noncon-
servative sequence changes (nonsynonymous/splice-sitel of Medicine, Guy’s Hospital, London SE1 9RT, UK; 2St John’s Institute of
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c.uk (J.N.B.)
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Figure 1. Clinical Features of Generalized Pustular Psoriasis
(A) Individual GPP-02 II:1. Note extensive plaques of erythema
with superimposed pustules on the arm.
(B) Individual GPP-01 II:5. Note erythematous, intensely inflamed
skin with active pustulation and desquamation on the buttocks.
(C) Individual GPP-03 II:2. Note widespread, healing erythema-
tous plaques following active pustulation on the legs.substitution or coding insertion/deletion occurring with
an estimated population frequency of < 0.01) in the
same gene, in all five individuals. Population-frequency
estimates were derived from the March 2011 data release
of the 1000 Genomes Project and from 250 control
exome variant profiles sequenced via the same method-
ology in our laboratory. The analysis failed to identify
a single gene fitting a rare recessive model in all five
individuals. However, evaluation of the data with a prior
expectation of genetic heterogeneity revealed IL36RN
(previously known as IL1F5, MIM 605507, RefSeq
NM_173170.1) as the only gene harboring low-
frequency variants compatible with recessive inheritance
in three of the five subjects (Table 2). Two (GPP-01 II:5
and GPP-02 II:1) were homozygous for a c.338C>T
(p.Ser113Leu) missense substitution, whereas the third
subject (GPP-03 II:2) was found to be compound hetero-
zygous for c.338C>T (p.Ser113Leu) and a c.142C>T
(p.Arg48Trp) missense substitution.
The identified variants were each confirmed by Sanger
sequencing (Figure 2). Genotyping of these substitutions
in available unaffected family members confirmed that
the segregation of the variants was consistent with a reces-
sive inheritance pattern for IL36RN-associated GPP
(Figure 2). Neither variant has been observed by the 1000
Genomes Project or observed in the homozygous state in
250 ethnically matched control individuals. A single
carrier of the c.338C>T (p.Ser113Leu) missense substitu-
tion was observed in our control cohort; no other coding
variation in IL36RNwas observed in this individual. Sanger
sequencing of the two individuals in whom no mutation
was identified by exome sequencing confirmed the wild-
type sequence. It is of note that PPP was observed inThe Americanthese two cases. PPP is a clinical feature not present in
the three individuals in whom we identified IL36RNmuta-
tions, these findings are therefore consistent with the
notion that mutation of IL36RN is responsible for a specific
subtype of GPP not associated with PPP. This specificity
was further supported by Sanger sequencing of the four
IL36RN coding exons and their associated splice sites in
a cohort of 30 individuals with a range of pustular forms
of psoriasis, including GPP, in individuals with preexisting
PV and PPP. Wild-type coding sequence was observed in
all subjects. In addition, no significant association of
common variation at the IL36RN locus with PV was
observed under recessive or additive models in data avail-
able from a large genome-wide association study of psori-
asis previously undertaken by our group (data not
shown).3 IL36RN has also been previously investigated in
psoriatic arthritis; although association was reported with
variants in other genes located within the IL1 gene cluster,
no direct association was observed with a variant located in
intron 1 of IL36RN (rs990524).6 More recently, a genome-
wide association study of psoriatic arthritis did not report
association to IL36RN locus.7
IL36RN belongs to the IL-1 cytokine family, which
comprises a group of evolutionary ancient cytokines with
potent and critical roles in innate immunity; a system of
cells, receptors, and mediators that provides a rapid and
nonspecific response to pathogens. There are 11 IL-1
family members, nine of which are clustered in a 400 kb
region on chromosome 2. Like many members of the IL-1
family, IL36RN and its paralogs IL36A (MIM 605509),
IL36B (MIM 605508), and IL36G (MIM 605542) (previ-
ously known as IL1F6, IL1F8, and IL1F9, respectively) are
abundantly expressed in skin. The proteins encoded by
these genes modulate NF-kB signaling, through their inter-
action with the IL-1RL2 receptor (previously known as
IL-1Rrp2).8,9 IL36RN in particular antagonizes the activity
of IL-36A and IL-36G, by blocking the recruitment of the
IL-1RL2 receptor complex.10 IL36RN itself consists of
a putative signal peptide followed by a large IL-1 homology
motif, thus reflecting the typical domain architecture
of IL-1 family cytokines.10 In this context, homology
searches and three-dimensional structural modeling
demonstrated that both the p.R48W and the p.S113L
mutation affect evolutionary conserved IL36RN residues.
which are located in close proximity to critical binding
residues (Figure 3).11 Both missense substitutions are pre-
dicted by SIFT to be damaging.12 To assess the functional
impact of the p.Ser113Leu mutation, we obtained periph-
eral-bloodmononuclear cells (PBMCs) from a homozygous
affected individual (GPP-02 II:1) and an unrelated healthy
volunteer. We examined the effect of IL-36A stimulation
on the production of four NF-kB-induced proinflammatory
cytokines (IL-1a, IL-6, IL-8, and TNF). After 7 hr of treat-
ment with 1 mg/ml IL-36A (R&D Systems), both intracel-
lular transcript levels (Applied Biosystems TaqMan Gene
Expression assays) and extracellular protein secretion
(Millipore MILLIPLEX MAP Human Cytokine/ChemokineJournal of Human Genetics 89, 432–437, September 9, 2011 433
Table 1. Clinical and Genetic Data for the Five GPP Cases in Whom Exome Sequencing Was Performed
Individual Gender Ethnicity Age at Onset (years) GPP PPP CPP
Inflammatory
Arthritis
Triggers of
Exacerbations
Past Treatments /
Responsea
Systemic Features
during Flares IL36RN Mutation
GPP-01 II:5 female European 51 yes no no no stress acitretin / no
methotrexate / no
ciclosporin / yes
fumaderm / no
etanercept / initial
infliximab / initial
adalimumab / partial
fever > 38C: yes
malaise: yes
CRP > 100 mg/l: yes
ESR > 50 mm/hr: yes
neutrophilia > 15 3
109/l: yes
c.338C>T (p.Ser113Leu)
GPP-02 II:1 male European 5 yes no no no stress, medication
(penicillin, codeine),
viral infection
prednisolone / yes
acitretin / no
methotrexate / yes
ciclosporin / yes
fever > 38C: yes
malaise: yes
CRP > 100 mg/l: yes
ESR > 50 mm/hr: yes
neutrophilia > 15 3
109/l: yes
c.338C>T (p.Ser113Leu)
GPP-03 II:2 female European 7 yes no no no stress, medication
(paracetamol), viral
infection, pregnancy
prednisolone / yes
acitretin / no
isotretinoin / no
methotrexate / yes
ciclosporin / yes
infliximab / yes
fever > 38C: yes
malaise: yes
CRP > 100 mg/l: yes
ESR > 50 mm/hr: yes
neutrophilia > 15 3
109/l: yes
c.142C>T (p.Arg48Trp)
and c.338C>T
(p.Ser113Leu)
GPP-04 I:1 female European 10 yes yes no no stress, pregnancy prednisolone / no
methotrexate / yes
ciclosporin / no
infliximab / yes
fever > 38C: yes
malaise: yes
CRP > 100 mg/l: no
ESR > 50 mm/hr: yes
neutrophilia > 15 3
109/l: yes
no mutation identified
GPP-05 I:1 female European 45 yes yes no no - acitretin / yes
ciclosporin / yes
fever > 38C: no
malaise: no
CRP > 100 mg/l: no
ESR > 50 mm/hr: no
neutrophilia > 15 3
109/l: no
no mutation identified
Abbreviations are as follows: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
a Response defined as treatment resulting in disease remission for > 1 month.
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Figure 2. Mutation and Segregation Analysis
(A) Pedigrees and mutation status of three GPP kindreds in whom mutations were identified in IL36RN.
(B) Sequence chromatograms of the c.338C>T (p.Ser113Leu) and c.142C>T (p.Arg48Trp) mutations.panel and a Luminex FLEXMAP 3D flow-based analyzer)
were measured. The induction of TNF mRNA was not
analyzed because the 7 hr time point exceeds the time
span of the gene transcriptional response. Both sets of
experiments demonstrated a marked increased in cytokine
production in the affected individual PBMCs (Figure 4), in
keeping with the notion that the p.Ser113Leu missense
substitution affects the ability of IL36RN to antagonize
IL36A-induced NF-kB signaling.
Inmice, abnormal Il-36 signaling due to Il1f6 (themouse
ortholog of IL-36A) overexpression results in transient skin
inflammation characterized by acanthosis, hyperkeratosis,
and a mixed-cell infiltrate rich in neutrophils,13 features
observed in both PV and GPP. When crossed with Il1f5
(the mouse ortholog of IL36RN)-deficient mice, the skin
phenotype is strikingly enhanced and persistent with
extensive pustule formation.13 Taken together, these data
provide the platform to postulate that GPP is caused by
abnormal IL-36A signaling resulting from IL36RN loss-of-
function mutations. The variable age at onset of clinical
manifestations of GPP in the three individuals in whomTable 2. Numbers of Candidate Genes Highlighted by Exome
Sequencing
Any x of five individuals 1 2 3 4 5
Genes with homozygous or
compound-heterozygous
nonsynonymous, splice-site, or
insertion/deletion variants
6721 5141 4030 3108 2162
With an estimated frequency < 0.01 80 5 1 0 0
The Americanwehave identifiedmutations in IL36RN suggests a complex
interaction among this major genetic determinant, poten-
tial environmental triggers, and/or additional genetic
modifiers. Interestingly mutations in another IL-1 family
receptor antagonist, IL1RN (MIM 147679), have recently
been reported to cause an autoinflammatory disease char-
acterized in part by pustular skin eruptions (MIM
612852).14,15 However, there are notable differences
between this disease and GPP, including neonatal onset
and major skeletal abnormalities. Finally, it is also of
interest that anakinra, a recombinant IL-1 receptor antag-
onist (IL-1RA), has been reported to be effective in two
individuals with GPP,16 providing evidence for the clinical
benefit of treatment targeting IL1 family pathways.
GPP is a severe, debilitating, and potentially life-threat-
ening disease. Our data indicate that mutations in
IL36RN underlie this distinct form of pustular disease,
separate from other forms of psoriasis. They implicate
defects of the innate immune system and highlight IL-1
signaling as a potential target for therapeutic intervention.Supplemental Data
Supplemental Data include three tables and can be foundwith this
article online at http://www.cell.com/AJHG/.Acknowledgments
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Figure 3. Location of the Two Identified Mutations
(A) Location of the two identified mutations with respect to the genomic organization of IL36RN (upper panel) and IL36RN (lower
panel).
(B) Locations of the c.142C>T (p.Arg48Trp) and c.338C>T (p.Ser113Leu) mutations with respect to the three-dimensional structure of
IL36RN, including the loop domains and critical residues that mediate receptor interaction.9
Figure 4. Analysis of Case and Control PBMCs, after Ex Vivo Stimulation with IL-36A
(A) The induction of IL1A, IL6, and IL8mRNAwas assessed by real-time PCR, with the RPLPO transcript used as an endogenous control.
Data are plotted as the mean, and error bars represent the SEM of duplicate stimulations with the expression level of the unstimulated
sample set as a baseline value. CTR, control.
(B) The concentration of IL-1a, IL-6, IL-8, and TNFwas assayed in the PBMC culturemedium. Data are plotted as themean, and error bars
represent the SEM of duplicate stimulations. All significance values were calculated via a one-way ANOVA test, followed by a Bonferroni
posttest. *p < 0.05, **p < 0.01, ***p < 0.001. CTR, control.
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